World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
Biotech companies at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
18 biotech companies are at World CDx 2026 — 22 presentations on the program. Most represented: Agenus (1 on the program), Compass Therapeutics (1 on the program), Immunome (1 on the program). 4 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–18 of 18 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Agenus Lexington, MA | |
Biotechnology company developing immuno-oncology antibodies, including an Fc-enhanced anti-CTLA-4 therapy, for cancer. | Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access Talk Thu Oct 8 11:30am Integrating Multimodal Baseline Biomarkers with Clinical Outcomes in Patients with Cold, Refractory Tumors, Treated with Fc-Enhanced Anti–CTLA-4 Antibody Therapy Biomarker discovery & translation |
Compass Therapeutics Boston, MA | |
Clinical-stage biotech developing antibody-based cancer therapies. | Chair Wed Oct 7 11:18am Stream chair Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD |
Immunome Bothell, WA | |
Clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates. | Chair Wed Oct 7 11:18am Stream chair Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access |
Pyxis Oncology Boston, MA | |
Clinical-stage oncology biotech developing antibody-drug conjugates, led by micvotabart pelidotin, an ADC targeting extradomain-B of fibronectin in the tumor matrix. | Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access Talk Thu Oct 8 1:40pm Assessing Histologic Biomarkers of Response to Micvotabart Pelidotin (MICVO), the First-in-Class ADC Targeting the Tumor Extracellular Matrix Protein Extradomain-B of Fibronectin Biomarker discovery & translationDigital pathology & spatial biomarkers |
Bantam Pharmaceutical Durham, NC | |
Clinical-stage company developing oral small-molecule cancer drugs that act on mitochondrial dynamics, led by BTM-3566 for diffuse large B-cell lymphoma. | Talk Wed Oct 7 2:40pm Advancing Precision Oncology: Developing Translational Biomarkers for a Novel Mitochondrial-Targeted Therapy Biomarker discovery & translation |
Beam Therapeutics Cambridge, MA | |
Biotechnology company developing base-editing medicines, including a gene-editing therapy for sickle cell disease. | Talk Wed Oct 7 11:50am Clinical Biomarkers in Gene Editing Therapy for Sickle Cell Disease Biomarker discovery & translation |
BioTheryx San Diego, CA | |
Develops protein degrader medicines for cancer and inflammatory disease. | Talk Thu Oct 8 11:50am Beyond Maximum Tolerated Dose: Using a Dynamic Pharmacodynamic Biomarker, TKa, for Oncology Drug Development Biomarker discovery & translation |
Candel Therapeutics Needham, MA | |
Clinical-stage company developing viral immunotherapies for solid tumors. | Talk Wed Oct 7 2:40pm Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial Biomarker discovery & translationDigital pathology & spatial biomarkers |
CREATE Medicines Cambridge, MA | |
Clinical-stage biotech using mRNA in lipid nanoparticles to program immune cells inside the body, including in vivo CAR therapies for solid tumors. | Panel Thu Oct 8 11:30am Seeing is Believing: Spatial Profiling of In Vivo CAR Myeloid Cell Activity in MT-302 & MT-303 Clinical Biopsies Digital pathology & spatial biomarkersBiomarker discovery & translation |
Eikon Therapeutics Millbrae, CA | |
Biotech using super-resolution live-cell imaging and other platforms to discover and develop medicines, mainly for cancer. | Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD |
Incendia Therapeutics Cambridge, MA | |
Develops antibodies that disrupt the tumor microenvironment, led by PRTH-101, a DDR1 inhibitor. | Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access |
MacroGenics Rockville, MD | |
Develops antibody-based cancer therapies, including bispecifics and antibody-drug conjugates. | Talk Thu Oct 8 2:30pm Deciphering Mechanisms of Resistance to ADC Therapy Biomarker discovery & translation |
Moderna Cambridge, MA | |
Develops mRNA medicines and vaccines, including individualized neoantigen cancer therapies. | Talk Wed Oct 7 9:40am The New Frontier of Precision Medicine – From Tumor Fingerprint to Dose: Integrating Data & NGS to Power Neoantigen Therapies Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
PTC Therapeutics Warren, NJ | |
Biopharmaceutical company developing and marketing treatments for rare diseases, including neuromuscular and metabolic disorders. | Talk Wed Oct 7 5:30pm Translational Pharmacology & Biomarker Strategy in Drug Discovery & Development Biomarker discovery & translation |
Rgenta Therapeutics Woburn, MA | |
Clinical-stage biotech developing oral small molecules that modulate RNA, aimed at hard-to-drug cancer proteins such as MYB and at repeat-expansion CNS diseases. | Panel Tue Oct 6 5:10pm The Role of AI in the Future of Companion Diagnostics Multimodal & AI-enabled precision medicineClinical & companion diagnostic development |
Rigel Pharmaceuticals South San Francisco, CA | |
Commercial-stage biotech selling therapies for hematologic disorders and cancer, including fostamatinib for immune thrombocytopenia and olutasidenib for IDH1-mutant AML. | Panel Wed Oct 7 3:10pm Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications Drug–diagnostic commercialization & access |
Tango Therapeutics Boston, MA | |
Precision oncology biotech developing drugs that exploit synthetic lethality in tumors with specific genetic losses, such as MTAP deletion. | Panel Tue Oct 6 12:30pm Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
Vanqua Bio Chicago, IL | |
Develops medicines for neurodegenerative diseases, led by a GCase-targeted program for Parkinson's disease and dementia with Lewy bodies. | Chair Thu Oct 8 10:58am Stream chair |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction